- $135.55m
- $118.16m
- $27.47m
US STOCKS ON THE MOVE-Meta, Marvell Technology, Insmed
U.S. STOCKS ON THE MOVE-Accenture, Arhaus, Alkermes
Cue Biopharma surges after positive results from mid-stage study for CUE-221
Brief: Cue Biopharma Announces Positive Topline Results From Cue-221 Phase 2 Study In Chronic Spontaneous Urticaria
Cue Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cue Biopharma Q2 revenue more than doubles, net loss widens on one-time charges
Cue Biopharma, Inc. expected to post a loss of $1.69 a share - Earnings Preview
Cue Biopharma Q1 net loss narrows on lower R&D costs
NASDAQ RESUMED AT 01:32 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:27 PM
NASDAQ RESUMED AT 10:10 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:05 AM
NASDAQ RESUMED AT 10:04 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:54 AM
NASDAQ RESUMED AT 09:52 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:47 AM
NASDAQ RESUMED AT 09:47 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:37 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:41 AM